Angiosarcoma

Angiosarcoma is a malignant tumour of endothelial cells that can arise in skin, soft tissue, breast, liver, spleen, heart, and bone. It is among the most aggressive of all sarcomas: it metastasises early by the haematogenous route, especially to the lung, it is multifocal locally, and it recurs locally at a high rate even after complete excision.

Who gets it. Angiosarcoma accounts for 1-2% of all soft tissue sarcomas. The age distribution is bimodal: young adults with deep soft tissue or visceral disease, and the elderly with cutaneous head and neck disease, where the scalp and face are the most common sites, typically in patients over 60. There is a slight overall male predominance, although breast and Stewart-Treves disease occur in women. Median 5-year survival across all sites is approximately 20-35%.

Established associations. The recognised causes are:

• Therapeutic radiation - breast most commonly
• Chronic lymphoedema - Stewart-Treves syndrome
• Chemical carcinogens - vinyl chloride, arsenic, thorotrast, classically hepatic angiosarcoma
• Chronic foreign bodies - vascular grafts, retained surgical material
• Ultraviolet exposure - a driver of the high mutational burden in cutaneous head and neck disease

Angiosarcoma arises from malignant transformation of vascular or lymphatic endothelial cells, producing irregular, anastomosing vascular channels lined by atypical endothelium that dissect through tissue planes. This infiltrative, channel-forming growth underlies two defining clinical problems: tumour extent is consistently underestimated at the margins, and disease is frequently multifocal, with "skip" lesions, which is why recurrence is high even after apparently complete resection. The same vasoformative phenotype accounts for the propensity to bleed and for the bruise-like appearance of cutaneous disease.

Secondary angiosarcoma. Post-radiation and lymphoedema-associated tumours carry high-level MYC (8q24) amplification in essentially 100% of cases, with FLT4 (VEGFR3) co-amplification in a subset. MYC amplification is absent in benign atypical vascular lesions, which makes it the key diagnostic discriminator in an irradiated field.

Primary angiosarcoma. These tumours generally lack MYC amplification and show other alterations: KDR/VEGFR2 mutations, PTPRB and PLCG1 mutations, and a high UV-signature mutational burden in cutaneous head and neck disease. Upregulation of the vascular receptor tyrosine kinases TIE1, KDR, TEK and FLT1 is the rationale for anti-angiogenic and tyrosine-kinase-directed treatment.

View larger

Cutaneous angiosarcoma of the head and neck. The classic patient is elderly and the lesion is on the scalp, the most common site. It looks like a bruise, purple or red, it enlarges rapidly over weeks to months, it is often multifocal with several areas of involvement, and there is no history of trauma, which is what separates it from a haematoma.

Radiation-induced angiosarcoma. It arises within the radiation field 5-10 years after radiotherapy, classically on the irradiated breast, as skin changes: redness, ecchymosis and palpable nodules. The differential is radiation dermatitis and inflammatory breast cancer.

Stewart-Treves syndrome. Angiosarcoma arising in chronic lymphoedema, classically the arm after mastectomy, with a latency that is usually greater than 10 years. It presents as purple nodules or plaques in the chronically oedematous arm, is rapidly progressive and is often multifocal.

View larger

View larger

Deep soft tissue angiosarcoma. A large mass in the extremity or trunk, often painless until late and growing rapidly. With bone involvement it may present with a pathological fracture.

Primary angiosarcoma of bone. This is rare, but it is the form most likely to present to the orthopaedic surgeon. Multifocality is characteristic: it is classically multicentric, with several lesions within one bone or clustered in a single limb or anatomical region, which is a recognised diagnostic clue, although solitary lesions occur.

What the radiograph shows. A permeative, lytic, destructive lesion with cortical breach and frequently a pathological fracture. Matrix is absent; the lesion is purely lytic.

View larger

What the histology shows. It is often epithelioid, which can mimic metastatic carcinoma; the endothelial markers CD31 and ERG are decisive. The differential of a destructive lytic bone lesion is:

• Epithelioid haemangioendothelioma - a lower-grade vascular tumour that can also be multifocal
• Haemangioma
• Metastatic carcinoma
• Myeloma

A multifocal lytic pattern in one region should prompt biopsy plus immunohistochemistry rather than the assumption of metastasis.

How it is treated. Management mirrors high-grade bone sarcoma: biopsy and full staging, including the lungs, before any intervention, then wide resection where feasible with or without radiotherapy and chemotherapy. High-grade disease carries a poor prognosis, and multifocality often precludes a curative resection. The registry survival data, and why the site of the lesion is the first thing to establish, are set out under Outcomes and Prognosis.

Algorithm

View larger

Surgical ManagementRadiation TherapyChemotherapy

The goal. Wide excision with 2-3cm margins where feasible, en bloc resection of all involved areas, and reconstruction as needed. What that means in practice differs by site:

Scalp angiosarcoma

Surgical Approach

Wide local excision, often requires skin grafting

Challenges

Multifocal disease makes complete excision difficult

Radiation-induced breast

Surgical Approach

Mastectomy + chest wall resection

Challenges

Extensive resection needed, often positive margins

Stewart-Treves (arm)

Surgical Approach

Amputation (often required)

Challenges

Limb salvage rarely achievable due to extent

Deep soft tissue

Surgical Approach

Wide excision + reconstruction

Challenges

Best chance of negative margins

Site	Surgical Approach	Challenges
Scalp angiosarcoma	Wide local excision, often requires skin grafting	Multifocal disease makes complete excision difficult
Radiation-induced breast	Mastectomy + chest wall resection	Extensive resection needed, often positive margins
Stewart-Treves (arm)	Amputation (often required)	Limb salvage rarely achievable due to extent
Deep soft tissue	Wide excision + reconstruction	Best chance of negative margins

When to amputate. Amputation is often necessary in Stewart-Treves syndrome to achieve local control, and the indications are:

• Stewart-Treves syndrome with extensive involvement
• Neurovascular encasement precluding limb salvage
• Recurrent disease after prior limb-sparing surgery
• Patient choice for local control

View larger

View larger

Indications. Radiotherapy is a standard adjuvant treatment despite the variable response, and is given for:

• Adjuvant after surgery, in all cases with high-grade disease
• Positive or close margins (under 1cm)
• Unresectable disease, as palliation
• Head and neck angiosarcoma, which is often unresectable

Dose. Adjuvant treatment is 60-66 Gy in 1.8-2 Gy fractions. Preoperative treatment is 50 Gy and may downsize the tumour; palliative treatment is 30-40 Gy.

What it achieves. Angiosarcoma has variable radiosensitivity. Radiation improves local control but does not eliminate the risk of recurrence; it is an essential component of multimodal therapy.

Where the evidence sits. Chemotherapy is indicated for metastatic or unresectable disease, and both the trial and the cohort data come from this population. It is also used neoadjuvantly for large or locally advanced tumours, to make an unresectable lesion resectable.

Adjuvant chemotherapy after complete resection of localised disease is widely given for high-grade angiosarcoma, but be clear in a viva that this is extrapolated from high-grade soft tissue sarcoma generally. No trial has shown that adjuvant chemotherapy improves survival in resected localised angiosarcoma; the survival gains demonstrated in the face and scalp cohorts came from adding radiotherapy to surgery, not chemotherapy. Decide it at the multidisciplinary meeting rather than reflexively.

First-line regimens.

• Weekly paclitaxel (80 mg/m² on days 1, 8, 15 of a 4-week cycle) - the ANGIOTAX phase II non-progression rate was 74% at 2 months and 45% at 4 months
• Doxorubicin-based (doxorubicin +/- ifosfamide) - the traditional high-grade sarcoma regimen; French Sarcoma Group data show doxorubicin and weekly paclitaxel give comparable first-line survival
• Paclitaxel + bevacizumab (anti-VEGF) - studied but adds toxicity without a clear survival gain

Second-line and emerging options.

• Gemcitabine +/- docetaxel
• Pazopanib, a tyrosine kinase inhibitor licensed for non-adipocytic soft tissue sarcoma
• Propranolol - a non-selective beta-blocker repurposed as an adjunct; beta-adrenergic signalling drives angiosarcoma proliferation and angiogenesis, and propranolol combined with chemotherapy (for example metronomic vinblastine/methotrexate or paclitaxel) has produced responses in case series, particularly in cutaneous angiosarcoma
• Clinical trials - immune checkpoint inhibitors are under investigation, particularly in cutaneous, UV-related disease with a high tumour mutational burden

What it achieves. Angiosarcoma has moderate chemosensitivity relative to other sarcomas. Taxanes are particularly favoured for cutaneous and scalp disease, and doxorubicin remains a reasonable first-line alternative. Chemotherapy delays progression and can downstage locally advanced disease, but cure is rare once metastatic.

View larger

Putting it together by subtype. The three modalities are combined differently for each clinical subtype:

Disease-related. Local recurrence, lung metastasis, haemorrhage from the tumour and post-resection lymphoedema are the disease-related complications; their incidence and management are in the table.

Treatment-related. Wound complications, meaning infection, dehiscence and flap necrosis, occur in 15-25%. Radiation toxicity is fibrosis and chronic pain, especially when re-irradiating; chemotherapy toxicity is neuropathy with paclitaxel and myelosuppression.

Surveillance is intensive because of the metastatic rate, and it continues indefinitely because late recurrences and metastases are possible.

Algorithm

View larger

Clinical subtype is the most important prognostic factor. Within a subtype, size, margin status, metastases and multifocality move the figure in the directions the table shows.

Why the scalp has the worst prognosis. Cutaneous angiosarcoma of the scalp does worst of all the subtypes because of multifocal disease at presentation, an infiltrative growth pattern, the difficulty of achieving negative margins, and an elderly patient population.

Why the scalp survival figure depends on who is counted. The two figures a candidate is likely to meet for face and scalp angiosarcoma differ by a factor of three, and both are correct for the population they describe. Unselected and older series, which include patients who were metastatic at diagnosis, frail, or never offered curative treatment, cluster around 10-20% at 5 years. Cohorts restricted to non-metastatic disease treated with curative intent report 5-year overall survival 43% and disease-specific survival 46% (Guadagnolo, n=70) and 5-year disease-specific survival 56% with local control 51% (Yoder, n=143, the largest series available). Both are level 3 retrospective evidence from a single tertiary sarcoma centre.

The practical consequence is a counselling error in the making. A patient in front of you with a resectable, non-metastatic scalp lesion who is fit for surgery plus radiotherapy has odds far closer to one in two than one in six, and quoting the unselected figure to them understates what treatment can achieve. The reverse error matters too: the better figures are achieved by combined-modality therapy, and in both cohorts single-modality treatment, tumours over 5 cm and multifocal disease were the factors that pulled survival back down.

Primary angiosarcoma of bone, and why the site of the lesion is the first thing to establish. Registry data on 458 patients separate the skeleton into two very different diseases. Appendicular tumours have a 5-year overall survival of 38%; axial tumours (spine, pelvis, ribs, skull) only 17%, and axial location remained an independent predictor of cancer-specific death after adjustment (subdistribution hazard ratio 1.62, 95% CI 1.25-2.10).

The gap is largely explained by three things that travel together: axial patients were markedly older (median 63 versus 46 years), were more often metastatic at diagnosis (43% versus 29%), and, the modifiable one, underwent surgery in only 37% of cases against 81% of appendicular tumours. A pelvic or spinal angiosarcoma is therefore not simply a worse tumour; it is frequently one that could not be resected, which is the argument for referring it to a centre that can attempt resection rather than assuming it is unresectable.

View larger

View larger

Global Epidemiology

Angiosarcoma accounts for under 2% of all soft tissue sarcomas and roughly 1-2% of cutaneous sarcomas, making it one of the rarest yet most lethal sarcoma subtypes worldwide. It shows a slight male predominance overall, with a median age of 60-70 years for the common cutaneous head/neck form. Geographic and historical variation reflects exposure patterns: thorotrast-associated hepatic angiosarcoma (now historical), occupational vinyl chloride exposure (hepatic angiosarcoma, industrialised regions), and the rising incidence of radiation-associated breast angiosarcoma in high-income settings as breast-conserving therapy with radiotherapy has become standard.

Side-by-Side Guideline Comparison

Angiosarcoma is rare enough that almost all evidence is retrospective; few questions are settled.